Pfizer will pay Allergan $150 million to reimburse expenses for the deal. Allergan CEO Brent Saunders said in a Bloomberg TV interview that the company will move forward to look for another possible deal. Saunders did not give a specific answer when asked if Allergan would look to buy the Bausch & Lomb segment from embattled Valeant ( VRX ), but said it was a "premier asset."